Progression-free and overall survival in ALK-Positive NSCLC patients treated with sequential Crizotinib and Ceritinib

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2745-2752

  Gainor, Justin F ^a   Tan, Daniel S W ^b   De Pas, Tomasso ^c   Solomon, Benjamin J ^d   Ahmad, Aziah ^b   Lazzari, Chiara ^c   De Marinis, Filippo ^c   Spitaleri, Gianluca ^c   Schultz, Katherine ^a   Friboulet, Luc ^a   Yeap, Beow Y ^a   Engelman, Jeffrey A ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ALK GENE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; BIOPSY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; AGED; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938266539     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3009     Document Type: Article

References (25)

1. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11.
2. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007;448:561-6.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
6. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
7. Mok T, Kim D, Wu Y, Solomon BJ, Nakagawa K, Mekhail T, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexedcarboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 32:5s, 2014 (suppl; abstr 8002).
8. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra17.
9. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
10. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-96.
11. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73.
12. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small cell lung cancer. N Engl J Med 2014;370: 1189-97.
13. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
15. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
16. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
17. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9.
18. Sequist L, Soria J, Gadgeel S, Wakelee HA, Camidge DR, Varga A, et al. Firstin-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 32:5s, 2014 (suppl; abstr 8010).
19. Janne P, Ramalingam S, Chih-Hsin J, Ahn MJ, Kim DW, Kim SW, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8009).
20. Awad M, Shaw A. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014;12:429-39.
21. Browning ET, Weickhardt AJ, Camidge DR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J Thorac Oncol 2013;8:e21.
22. Gouji T, Takashi S, Mitsuhiro T, Yukito I. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol 2014;9:e27-8.
23. Felip E, Kim D, Mehra R, Tan DSW, Chow LQ, Camidge DR, et al. Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK=) non-small cell lung cancer (NSCLC): An update of ASCEND-1. European Society of Medical Oncology 2014 Congress, 2014;90:S33-S34. Abstract nr 1295P.
24. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small cell lung cancer (AF-001JP study): A single-Arm, open-label, phase 1-2 study. Lancet Oncol 2013;14:590-8.
25. Inoue A, Nishio M, Kiura K, Seto T, Nakagawa K, Maemondo M, et al. One-year follow-up of a phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2013;8:(S2). Abstract nr P3.11-034.